When The Pill Catches Up With The Needle: Oral Cyclic Peptides in 2026

Oct 13, 2026 Leave a message

In September, Novo Nordisk handed a deal worth up to USD 1.4 billion to Orbis Medicines, a Danish biotech, to invent, with the help of AI, oral macrocyclic drug candidates. The timing was telling: in the six months before that announcement, regulators on both sides of the Atlantic had approved three new cyclic peptide drugs in quick succession, turning what was long considered the toughest de novo molecular modality to crack from a laboratory talking point into a commercial reality.

 

Biosynergy Pharmaceutical

 

Three Approvals in Five Months

 

The story begins on March 18, when Johnson & Johnson announced that the FDA had approved Icotyde (generic name: icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older weighing at least 40 kg. It is the world's first oral cyclic peptide antagonist of the IL-23 receptor - and the first oral targeted peptide of its kind. In the company's statement, Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health, captured the pitch in a single line: Icotyde "delivers something unique in psoriasis treatment - combining skin clearance with a favorable safety profile in a once-daily pill." Wall Street, however, was already pricing in the promise: early consensus peak-sales estimates ran north of USD 5 billion.

 

Icotyde did not leave that number standing for long. In its 2026 second-quarter earnings, Johnson & Johnson disclosed that, in its first full commercial quarter on the market, the drug had filled more than 18,000 prescriptions and reached roughly 11,000 patients. The company then made an unusually direct statement: Icotyde is on track to become one of the largest launches in Johnson & Johnson's history - a line the market read as an implicit upgrade of peak-sales expectations to around USD 10 billion.

 

Four months later, the field turned to cardiometabolic disease. On July 16, the FDA approved Merck's enlicitide (brand name: Lipfendra) - the first and only oral PCSK9 inhibitor, a macrocyclic peptide. In the Phase III CORALreef program, a 20-mg once-daily oral dose cut LDL-C by up to 59.7%, putting it within striking distance of injectable PCSK9 monoclonal antibodies. Ann Marie Navar, MD, PhD, lead author of the CORALreef Lipids study and Associate Professor of Medicine at UT Southwestern Medical Center, summed it up: "Now, for the first time, patients have an oral PCSK9 inhibitor for LDL lowering." Merck Research Laboratories President Dean Y. Li, MD, PhD, called the approval "a pivotal moment."

 

On August 28, Takeda's rusfertide (brand name: Mimrylo) was approved for polycythemia vera (PV). A first-in-class hepcidin-mimetic peptide and a cyclic peptide by structure, rusfertide targets an entirely new mechanism - regulation of iron homeostasis. In the Phase III VERIFY study, 76.9% of patients on rusfertide achieved a clinical response during weeks 20 to 32, against 32.9% on placebo.

 

Three "world firsts" in five months, across autoimmune disease, cardiometabolic disease and a rare hematologic malignancy. Cyclic peptides' clinical viability no longer needs a research paper to make the case.

 

Why All the Excitement About a Pill

 

To make sense of the excitement, it helps to look at who - or what - cyclic peptides are up against.

 

Peptide drugs come in two structural flavors: linear and cyclic. The blockbusters to date - semaglutide and tirzepatide - are linear peptides, with stunning efficacy but delivered by injection. Cyclic peptides close the peptide chain into a ring, and the properties change with it: greater resistance to gastric acid and proteases, longer half-lives, sharper target affinity and biological activity, efficacy at lower doses, and reduced off-target effects and systemic toxicity. In plain terms, they try to deliver at once the convenience of a small-molecule pill and the potency of an injectable biologic.

 

Biosynergy

 

In chronic diseases - the autoimmune and metabolic conditions that require lifelong treatment - that combination looks close to a decisive advantage. Take the IL-23 inhibitor market: today it is ruled by three injectable biologics - Skyrizi (peak-sales consensus above USD 20 billion), Tremfya (above USD 10 billion) and Stelara (above USD 11 billion) - but injection administration, cold-chain storage, and the simple fear of needles all keep adherence from where it could be. Studies show that roughly 90% of patients currently on subcutaneous or intravenous therapy would switch to an oral option if efficacy and safety were comparable; meanwhile, in psoriasis and inflammatory bowel disease, an estimated 50% to 70% of patients - around 5 million people in the United States alone - are eligible for advanced therapies but have never received one. Oral formulations can dramatically lower the barrier to treatment and lift penetration. In other words, cyclic peptides are not just eyeing replacement of an existing pie; they are looking at a wholly untouched one.

 

And the opportunity does not stop at replacement. According to research from Sinolink Securities, the molecular weight of cyclic peptides sits precisely in the structural gap between small molecules (under 500 Da) and antibodies (above 5,000 Da). They can engage the broad, flat interfaces of protein-protein interactions (PPIs) with high affinity, and they are also credible candidates for crossing cell membranes to reach intracellular targets such as KRAS - and even intrinsically disordered proteins (IDPs) - the traditional "undruggable" targets that small molecules cannot reach and antibodies cannot enter.


Roche's Chugai Pharmaceutical has already pushed this blueprint into the clinic: its oral pan-KRAS cyclic peptide inhibitor AUBE00 is currently in Phase I, going after the textbook "undruggable" target. And cyclic peptide design is, in its own right, an engineering discipline: three variables - cyclization scaffold (mono-, bi- or tricyclic), cyclization site (head-to-tail, head-to-side, side-to-tail, side-to-side), and chemical modification (methylation, glycosylation, lipidation, thioether bridges in place of disulfide bonds, and others) - combine to determine a molecule's fate.

 

What is striking is the asymmetry of the industry's enthusiasm. So far this year, roughly 400 new ADC programs have entered the global pipeline - a dust cloud of activity. The number of new cyclic peptide programs? Eleven. The high barrier to entry has kept the field thin, and the position of the early players all the more visible.

 

China's Supply Chain Is Lit Up

 

The prescription curves of Icotyde and enlicitide are already working their way upstream through the supply chain.


Hansoh Pharmaceutical's HS-20118 is the first China-originated oral IL-23R cyclic peptide to enter late-stage clinical development, ranking among the top three globally for the same mechanism of action. A Phase II in psoriasis has been initiated in China, with a global Phase II planned for early 2027, and the program is positioned to expand into ulcerative colitis, Crohn's disease and psoriatic arthritis. Its differentiation is written into its pharmacokinetics: through PEGylation and long-chain fatty-acid modification, the half-life has been extended to roughly 100 hours, opening the door to once-weekly oral dosing - versus Johnson & Johnson's Icotyde at once-daily - and putting HS-20118 alone in the white space of oral weekly autoimmune therapy. In a Phase I psoriasis cohort, the 25-mg once-daily dose group achieved an IGA 0/1 response rate of 87.5%.

 

In June, Hansoh licensed the ex-China rights to HS-20118 to Avere Therapeutics under a NewCo structure, with a USD 120 million upfront and a total deal value exceeding USD 2.3 billion. On July 14, Avere entered into an all-stock merger agreement with Nasdaq-listed NextCure, taking the combined entity public under the ticker "AVRX"; Hansoh is expected to hold 30% to 40% of the post-merger company and two of its five board seats. Avere's leadership team is no stranger to the playbook: it had run Akero Therapeutics from pre-IPO through to its USD 5.2 billion acquisition by Novo Nordisk in December 2025. Avere's CEO Andrew Cheng, MD, PhD, put it this way: "We are focused on rapidly delivering a once-weekly oral IL-23 therapy that combines best-in-class convenience with efficacy competitive with other emerging oral IL-23 therapies."


Three other Chinese players are moving fast in oral autoimmune cyclic peptides. Shanghai Henlius Biotech has built its own cyclic peptide platform, with the first asset - HLX702, an oral IL-23R cyclic peptide - about to enter the clinic, targeted at psoriasis, psoriatic arthritis and inflammatory bowel disease. Haisco Pharmaceutical's HSK47388 uses amide-bond cyclization and a bicyclic design to lift oral bioavailability; Phase I data show a half-life of 16 to 18 hours supporting once-daily dosing, and Phase II trials in psoriasis and ulcerative colitis are already underway in China. Sunshine Guojian Pharmaceutical's SSGJ-629 is still preclinical but is designed for once-weekly oral dosing.


On the cardiometabolic side, China's story is only just beginning. Almost all of the country's oral cyclic peptide programs are aimed at autoimmune disease; the only company with an oral asset in the clinic is Salubris Pharmaceuticals - its SAL0167 received IND clearance in July to start a Phase I trial in hyperlipidemia (announced July 8), a proprietary cyclic peptide.

 

Whichever molecule crosses the finish line, scale-up will inevitably run through the Chinese supply chain. Cyclic peptides have low oral bioavailability, so the amount of active material per dose can be many-fold higher than for an injectable; the molecules themselves are complex, the synthetic routes are long and yields are low, and commercialization is far more dependent on a mature industrial chain than for a typical small molecule. According to research from Caitong Securities, the commercial launches of Johnson & Johnson's and Merck's oral cyclic peptides - particularly Icotyde's faster-than-expected uptake - will directly lift sentiment in upstream non-natural amino acids and consumables (Chengda Pharmaceuticals, Sunresin New Materials) and in the cyclic peptide CDMO space (WuXi AppTec, Porton Pharma, Pharmaron, Viva Biotech, Apeloa Pharmaceutical).

 

The Scaffolding That AI Is Putting Up

 

As cyclic peptides move from "hardest to design" to "designable at scale," AI is the variable that cannot be left out. AI tools are now contributing to membrane permeability prediction, conformational prediction and free-energy calculation, structure-based rational design, and automated synthesis verification - all the places where the modality's hardest problems live.


Novo Nordisk's deal with Orbis is the freshest example. Orbis's nGen platform is a "lab-in-the-loop" system: it starts with a DNA-encoded library (DEL) of nearly 100 billion compounds to find initial hits, then uses generative AI to design macrocyclic molecules with diverse scaffolds, side chains and physicochemical properties, and finally synthesizes and analyzes up to around 100,000 compounds in a matter of weeks through automated chemistry and screening, with each round of real experimental data flowing back into the model. As Orbis CEO Morten Graugaard put it, "The future of oral biologic drug discovery lies at the intersection of AI, proprietary experimental macrocycle datasets, and world-class automated chemistry.


On the Chinese side, the names to watch are XtalPi, HitGen, Insilico Medicine and Boji Medical. HitGen, in particular, completed a DEL-based cyclic-peptide-like discovery platform in the first half of 2026: a library of more than 500 billion molecules, more than 1,500 non-natural amino-acid building blocks to expand structural diversity, and a target-to-PCC timeline as short as eight months. The company has also built a high-throughput synthesis, optimization and evaluation platform for cyclic-peptide-like molecules, supported by a database and AI platform covering nearly 9,000 such molecules.

 

Peptides are a field where champions keep emerging in clusters. The first wave of the GLP-1 revolution is not yet done, and the second wave - of cyclic peptides - has already arrived. This time, the eye of the storm is not in a syringe. It is in a pill